The Impact of Hepatic Steatosis on Survival After Pancreaticoduodenectomy (NCT07182136) | Clinical Trial Compass
CompletedNot Applicable
The Impact of Hepatic Steatosis on Survival After Pancreaticoduodenectomy
200 participantsStarted 2015-01-01
Plain-language summary
We will use simple summaries, educational handouts, and discussions with doctors and nurses to explain this study. The study looks at patients with early-stage pancreatic cancer who undergo pancreaticoduodenectomy (Whipple surgery). We found that some patients develop fatty liver (non-alcoholic fatty liver disease, NAFLD) within six months after surgery, which can affect nutrition, blood sugar control, and long-term survival.
To help patients and families understand, we will:
1. Provide clear written information sheets about the purpose of the study and its findings.
2. Use diagrams or plain-language explanations of terms like "pancreatic exocrine function" and "fatty liver."
3. Share results with healthcare providers so they can guide patients in nutrition, enzyme replacement, diabetes monitoring, and follow-up care.
4. Offer contact information for the research team to answer questions.
Who can participate
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults with stage I-II pancreatic ductal adenocarcinoma.
* Underwent curative-intent pancreaticoduodenectomy (conventional or pylorus-preserving).
* Surgery between January 2015 and May 2023.
* Complete clinical and imaging data available.
* Survived at least 6 months postoperatively.
Exclusion Criteria:
* Preoperative hepatic steatosis
* Incomplete clinical or imaging data
* Death within 6 months after surgery
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Incidence of postoperative nonalcoholic fatty liver disease (NAFLD)